Zogenix Risk Management Strategy For Zohydro ER Includes Capping Sales Rep Compensation
This article was originally published in The Pink Sheet Daily
Executive Summary
Abuse potential of the single-entity hydrocodone will be key factor during the Anesthetic and Analgesic Drugs Products Advisory Committee’s review, and the company is hoping to allay those concerns by offering promotional restrictions and a Risk Evaluation and Mitigation Strategy stricter than the one for extended-release/long-action opioids.
You may also be interested in...
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Prescriber training courses to be provided through continuing medical education venues are to be available by March 1, 2013. Changes from the draft are subtle, but indicate FDA’s focus on preventing incorrect use of the high-dosage narcotics and protecting patients.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.